RBC Capital reported on (NYSE:VRX) Valeant Pharma, bumping its target price to $36 today

August 14, 2016

Finance News

Having a price of $28.16, Valeant Pharma (NYSE:VRX) traded 1.76% higher on the day. With the last stock close down 38.14% from the 200-day moving average, compared with the Standard & Poor’s 500 Index which has fallen 0.00% over the same time. VRX has recorded a 50-day moving average of $22.66 and two hundred day average of $40.28. 20,621,851 shares of Valeant Pharma were exchanged, down from an average volume of 28,670,000

RBC Capital upped the target price of Valeant Pharma (NYSE:VRX) to $36, indicating a possible upside of 0.28%,

Previously on 8/09/2016, Rodman & Renshaw released a statement for Valeant Pharma(NYSE:VRX) suggesting “Buy” with a target price of $81 that suggested an upside of 2.61%.

See Chart Below:

Valeant Pharma (NYSE:VRX)

In addition to RBC Capital reporting it’s target price, a total of 18 analysts have reported on the company. The average target price is $43.56 with three analysts rating the company a strong buy, two firms rating the company a buy, 10 analyts rating the stock a hold, four brokerages rating the company to underperform, and finally one analystrating the stock as sell.

Valeant Pharma has a one-year low of $18.55 and a 52 week high of $252.51. Valeant Pharma’s market cap is currently $8.7B.

Brief Synopsis On Valeant Pharma (NYSE:VRX)

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, and Crystalens and Trulign.

Comments are closed.